Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Repligen Co. (NASDAQ:RGEN) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $190.25.

RGEN has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. UBS Group reduced their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Finally, Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th.

Repligen Stock Up 2.2 %

Shares of NASDAQ:RGEN opened at $149.99 on Friday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm’s 50-day simple moving average is $140.58 and its 200-day simple moving average is $142.84. The company has a market cap of $8.40 billion, a price-to-earnings ratio of -405.37, a PEG ratio of 4.40 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.23 EPS. As a group, equities research analysts predict that Repligen will post 1.52 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently added to or reduced their stakes in the business. O Shaughnessy Asset Management LLC grew its holdings in Repligen by 6.9% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 125 shares during the period. UniSuper Management Pty Ltd increased its position in Repligen by 100.0% during the first quarter. UniSuper Management Pty Ltd now owns 800 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 400 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in Repligen by 1.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 38,559 shares of the biotechnology company’s stock worth $7,086,000 after purchasing an additional 567 shares during the period. Advisors Asset Management Inc. raised its stake in Repligen by 21.6% during the first quarter. Advisors Asset Management Inc. now owns 13,827 shares of the biotechnology company’s stock worth $2,543,000 after purchasing an additional 2,456 shares during the period. Finally, Lazard Asset Management LLC boosted its holdings in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.